ArticleDiscover oncology2026
A novel NETosis-related gene signature for predicting prognosis and immunotherapy response in hepatic cancer.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Neutrophils expelling neutrophil extracellular traps (NETs) during the process of NETosis play a critical role in tumor development. In this study, we aimed to identify a prognostic NETosis-related gene signature that could predict the immunetherapy response and explore the expression of these genes in hepatocellular carcinoma (HCC). Differentially expressed NETosis-related genes were identified from the GSE80489 dataset in the Gene Expression Omnibus (GEO), and a protein-protein interaction (PPI) network was constructed using Cytoscape and the STRING database. Gene Ontology (GO) enrichment analysis revealed associations with chemical stimuli and the positive regulation of cellular processes in HCC. A total of 37 differentially expressed NETosis-related genes were identified, and SNORA31, PMAIP1, GLA, CXCL1, and ADM were selected to construct a prognostic signature. In the training cohort, the low-risk group demonstrated significantly better overall survival (OS) compared to the high-risk group (P = 2.715e-06), and multivariable analysis confirmed that this signature was an independent prognostic factor for HCC (HR = 1.630, 95% CI = 1.295-2.052, P < 0.001). This signature also significantly predicted OS in validation cohorts (P = 9.704e-03) and was associated with HCC patients' OS according to the Kaplan-Meier Plotter. Moreover, it could predict the immunotherapy response in HCC patients. Finally, we investigated the expression of NETosis-related genes in single-cell subtypes and in the HepG2 cell line, providing further insights into their relevance in HCC. Overall, this NETosis-related gene signature serves as a prognostic indicator and a potential predictor for immunotherapy response in HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.